---

• n  a secondary consequence

News & Articles

---

• Sequella Acquires Exclusive Worldwide Rights To Pfizer's Sutezolid, Currently In Clinical Development For Tuberculosis
  Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, recently announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB)
  July 22, 2013 - DrugDiscoveryOnline
• Gazette.Net: Earnings & Deals
  Rockville biotechnology company Sequella has licensed Pfizer Inc. ’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic in development for the treatment of tuberculosis.
  July 19, 2013 - Gazette.net